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Background: Recent meta-analyses revealed an association between type 2 diabetes mellitus (T2DM) and cancer.
The strongest relationship was demonstrated for liver and pancreatic cancer, followed by endometrial cancer. We
aimed at assessing the association between T2DM and cancer specifically for Tyrolean patients.
Methods: We investigated cancer incidence in Tyrolean subjects with T2DM by linking the data from the Diabetes
and the Cancer Registries. 5709 T2DM patients were included and the sex- and age-adjusted standardized incidence
ratio (SIR) was calculated, cancer incidence in the Tyrolean population serving as the standard. Endpoints were the
time at which cancer was diagnosed, death or end of the observation period (31 December 2010).
Results: Site-specific analyses revealed statistically significantly elevated SIRs for cancer of the pancreas (1.78, 95% CI
1.02, 2.89) and corpus (1.79, 95% CI 1.15, 2.66) for women, and cancer of the liver (2.71, 95% CI 1.65, 4.18) and
pancreas (1.87, 95% 1.11, 2.96) for men. Sub-analyses performed according to the time of diabetes diagnosis
revealed that SIR was highest in the first year after diabetes diagnosis, but SIR was demonstrated to be elevated in
women for cancer of the liver (SIR 3.37, 95% CI 1.24, 7.34) and corpus (SIR 1.94, 95% CI 1.09, 3.20) and in men for
liver (SIR 2.71, 95% CI 1.40, 4.74) in the period more than five years after diabetes diagnosis. In addition, increased
risk at borderline statistical significance was observed in females for liver cancer (SIR 2.40, 95% CI 0.96, 4.94) and
cervical cancer (SIR 1.81, 95% CI 0.87, 3.32) and in males for kidney cancer (SIR 1.65, 95% CI 0.99, 2.57).
Conclusion: This study revealed a higher risk for cancer at certain sites in Tyrolean patients with T2DM. However, it
is important to interpret the results with great caution due to inherent methodological problems. Optimized care
programs for patients with T2DM should be integrated into the recommended procedures for cancer screening.
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Diabetes mellitus and cancer are both common health
problems and an association between these two condi-
tions was demonstrated by several epidemiological stud-
ies. Large meta-analyses have evaluated the increased
risk of distinct cancer entities. An about twofold in-
creased risk for patients with type 2 diabetes mellitus
(T2DM) was found for liver cancer (2.01, 95% confi-
dence interval (CI) 1.61, 2.51 [1]), pancreatic cancer* Correspondence: willi.oberaigner@tilak.at
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distribution, and reproduction in any medium(1.94, 95% CI 1.66, 2.27 [2,3]) and endometrial cancer
(2.10, 95% CI 1.93, 3.24 [4]), and a less than twofold in-
creased risk for breast cancer (1.20, 95% CI 1.12, 1.28 [5]),
colorectal cancer (1.27, 95% CI 1.21, 1.34 [6]), kidney cancer
(1.42, 95% CI 1.06, 1.91 [7]), bladder cancer (1.24, 95% CI
1.08, 1.42 [8]) and non-Hodgkin's lymphoma (1.19, 95% CI
1.07, 1.32 [9]). The risk for T2DM patients to develop pros-
tate cancer was demonstrated to be reduced (0.84, 95% CI
0.76, 0.93 [10]), and data about the relation between diabetes
mellitus and various other cancer sites like gastric cancer
did not provide conclusive results [11-13].
The underlying mechanisms responsible for the in-
creased risk for certain cancer types in T2DM seem totral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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evidence suggests that obesity, insulin resistance and
hyperinsulinaemia are main risk factors for cancer
[2,4,14]. Hyperinsulinaemia is associated with an in-
creased cancer incidence and progression [15]. The tumor
growth-promoting role of hyperglycaemia seems to be
dependent on the presence of insulin resistance and hyper-
insulinaemia [15,16]. Finally, certain T2DM diabetes melli-
tus therapies are discussed with respect to their relationship
to cancer risk in T2DM [17].
From the epidemiological point of view, a number of
serious methodological problems have been discussed
like latency periods, lead time bias, reverse causality,
ascertainment bias and competing risks [18]. In conse-
quence, especially results from observational studies
have to be interpreted with great caution.
To the best of our knowledge, no epidemiological
studies on the relationship between diabetes mellitus
and cancer have been conducted in the Central European
region. In Tyrol, the Cancer Registry Tyrol (CRT) pro-
spectively collects all incident cancer cases since year
of diagnosis 1988 and the Diabetes Registry Tyrol
(DRT) registers diabetes mellitus patients attending
out-patient departments in Tyrol since 2005. Cancer
incidence rates in Tyrol are in the range of rates in
Central European countries (with the exception of high
prostate cancer rates and high melanoma rates). Com-
pleteness of overall incidence and site-specific inci-
dence has been shown to be high (≥ 97%) [19]. The
Tyrolean population of about 700 000 is very stable
with only minor out-migration, which facilitates cohort
studies. As Tyrol is, to the best of our knowledge, the
only population in Central Europe covered by a diabetes
registry, we felt it would be valuable to investigate the asso-
ciation between diabetes and cancer incidence. Therefore,
bearing in mind the great clinical importance of cancer risk
for diabetes patients in the interest of optimizing care for
diabetic patients and developing standardized control pro-
cedures, we aimed to assess the association between T2DM
and cancer specifically for Tyrolean patients. Our study
findings could serve as a model for the situation in Central
Europe and could support cancer screening recommenda-
tions for the local T2DM population.
Methods
The DRT was established in 2005 and registers all patients
with type 1 diabetes mellitus, T2DM and gestational dia-
betes mellitus, who are attending the out-patient depart-
ments of hospitals in Tyrol. We collected all newly
diagnosed diabetes patients since 2005 as well as all preva-
lent diabetes patients who attended an out-patient depart-
ment since 2005 for whatever reason. For the latter group
we attempted to retrospectively assess the date of diabetes
diagnosis. However, a non-negligible group of patientscould not remember their date of diagnosis. Therefore,
all patients collected by the DRT to date (N = 7627)
can be divided into a group of patients with registered
date of diabetes diagnosis (N = 5709, 75% of all patients)
and a second group of patients without registered date
of diagnosis. Compared to international prevalence esti-
mates, the DRT covers about 15% of all prevalent diabetes
patients in Tyrol.
Patient registration is performed using a standardized
questionnaire covering basic data on patient charac-
teristics and data on out-patient visits. The question-
naire includes age, sex, body height and body weight,
type of diabetes mellitus, diabetes mellitus treatment,
HbA1c, frequency of severe hypoglycaemia, physical
exercise and late complications of diabetes mellitus
(nephropathy, retinopathy, neuropathy, foot complications,
amputation, myocardial infarction, apoplexy, peripheral
arterial insufficiency, coronary artery bypass/PTCA).
Patient registration is done on a pseudonymised basis.
The pseudonymisation process permits linkage of data
for a specific patient registered in different departments
and guarantees data confidentiality, because pseudony-
misation prevents identification of the patient.
The CRT was established in 1986. Cancer data for the
Tyrolean population have been registered on a population
basis since 1988. Registration is performed from a standard-
ized questionnaire including sex, age at diagnosis, cancer
site and histology, date of diagnosis, stage and basic infor-
mation on primary cancer treatment. The CRT routinely
assesses patient survival status in a passive way. We employ
a probabilistic record linkage method to combine incidence
data and the official mortality data for Tyrol collected by
Statistics Austria. A detailed analysis of completeness and
validity of data items has been published [19]; incidence
data since year of diagnosis 1988 have been accepted for
publication in Cancer Incidence in Five Continents.
The cohort we analyzed was defined as all patients
registered by the DRT with defined date of diabetes
diagnosis. In order to assess cancer diagnosis for these
patients, record linkage between DRT and CRT was per-
formed after pseudonymising CRT data with the same algo-
rithm as applied in the DRT. We linked DRT patients to all
invasive cancer sites except non-melanoma skin cancer
(NMSC) diagnosed in the time period 1988 to 2010.
Like in most cancer registries, collection of NMSC data
in Tyrol has not been complete and therefore these data
were excluded; death certificate only (DCO) cases were
excluded, too. For patients with multiple cancer diagno-
ses, only the chronologically last cancer diagnosis was
included in the analysis in order to weaken reverse caus-
ality by study design as far as possible.
We calculated age-standardized incidence ratios treating
diabetes mellitus patients as a cohort. Entry date was date
of diabetes diagnosis (1st of January of the respective year,
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was before 1988, entry was determined to be 1 January
1988 because cancer data were not registered before 1988.
Every patient with cancer diagnosis except NMSC was
counted as an event, patients who died before cancer diag-
nosis or who were alive on 31 December 2010 without
cancer diagnosis were analyzed as censored. The number
of expected cancer cases was computed given the cancer
risk in the general population as standard, after adjusting
for sex, age in 5-year age groups and period in 5-year
period groups. SIR was calculated in the classical way by
observed cases divided by expected cases for all cancer sites
combined and for specific cancer sites. Confidence intervals
were computed by applying an exact method [20].
In order to determine whether a priori fixed design
rules influenced our results, we performed a sensitivity
analysis by 1) taking the chronologically first cancer
diagnosis instead of the last cancer diagnosis and 2)
defining a cohort of all patients registered in the DRT
(N = 7627), with or without registered date of diabetes
diagnosis. The population in Tyrol was 707 485 inhabi-
tants in 2010, of which 51.1% were females. All statis-
tical analysis was conducted using STATA statistical
software, version 11 [21].
Results
We analyzed a cohort of 5709 T2DM patients with
well-defined date of diabetes diagnosis, all of whom were
treated in out-patient departments of Tyrolean hospitals.
Of these patients, 2685 were female (24 145 person years)
and 3024 were males (25 697 person years). Mean age at
onset was 60 and 55 for females and males, respectively.
Mean HbA1c measures were 7.7%, 38.5% of patients showed
late complications. Further details on patient characteristics
are shown in Table 1.
Age-standardized cancer incidence rates for the most
recent period were 259 and 332 for 100 000 females and
males, respectively. Median age at diagnosis of cancer
patients was 66 years for females and 66 for males,
19%/13% were younger than 50 years and 19%/13%
older than 80 years for females and males, respectively.
The most common cancer sites among women were
breast cancer (28%), colorectal cancer (12%), lung cancer
(7%) and melanoma (6%) and among men prostate cancer
(28%), lung cancer (14%), colorectal cancer (11%), stomach
cancer (5%) and melanoma (5%). More details on cancer
incidence, especially age-standardized incidence rates for
Tyrol and for many cancer registries worldwide, have been
published elsewhere [22,23].
For female diabetes mellitus patients, 234 cancer
diagnoses were assessed. In the site-specific analysis
we found a statistically significantly elevated SIR for
pancreatic cancer (SIR = 1.78, 95% CI 1.02, 2.89) and cor-
pus cancer (SIR = 1.79, 95% CI 1.15, 2.66). Increased risks,although not statistically significant, were also observed for
liver and cervical cancer. Details are shown in Table 2.
For male patients, a total of 291 cancer diagnoses were
assessed. The site-specific analysis showed a statistically
significantly elevated SIR for liver cancer (SIR = 2.71, 95% CI
1.65, 4.18) and pancreatic cancer (SIR = 1.87, 95% CI
1.11, 2.96) and borderline significance for kidney cancer
(SIR = 1.65, 95% CI 0.99, 2.57). Details are shown in Table 2.
Sub-analysis performed according to the time elapsed
since diabetes diagnosis revealed that for females (Table 3),
in the first year after diabetes diagnosis, SIR was statistically
significantly elevated for pancreatic cancer (SIR = 9.51,
95% CI 3.82, 19.59), postmenopausal breast cancer
(SIR = 1.99, 95% CI 1.00, 3.57) and for cervical cancer
(SIR = 6.22, 95% CI 1.69, 15.92). No statistically signifi-
cant increased SIR was found during the period two to
five years after diabetes diagnosis, while in the period
beyond five years after diabetes diagnosis SIR was elevated
for liver cancer (SIR = 3.37, 95% CI 1.24, 7.34) and corpus
cancer (SIR = 1.94, 95% CI 1.09, 3.20). For male patients
(Table 4) we observed statistically significantly elevated
SIR for kidney cancer (SIR = 4.64, 95% CI 1.51, 10.83) in
the first year after diabetes diagnosis and for liver cancer
at 3.02 (95% CI 1.21, 6.21) and 2.71 (95% CI 1.40, 4.74) in
the periods two to five years and beyond five years after
diabetes diagnosis, respectively.
For all cancer sites combined, SIR was estimated at 1.05
(95% CI 0.92, 1.20) for females and at 0.93 (95% CI 0.82,
1.04) for males. However, the risk for all cancer sites com-
bined is prone to a different site mix for females than for
males (sex specific entities, different frequencies of some
sites like lung or head&neck between females and males)
and therefore must be interpreted with caution.
The results of the sensitivity analysis are shown in
Figures 1 and 2. For all sites with statistically significantly
elevated SIR the risk was of comparable size for all three
scenarios analyzed. However, there was a tendency towards
higher SIR estimates in the cohort of all DRT patients, with
and without registered date of diabetes diagnosis.
Discussion
This study combined the data of two Tyrolean registries,
the Diabetes Registry and the Cancer Registry, and
showed increased risks for liver and pancreatic cancer
in both male and female T2DM patients. In addition,
the cervix and corpus uteri cancer risk was elevated in
females and the kidney cancer risk in males. When ana-
lyses by time since T2DM diagnosis were performed the
most increased risk for liver cancer was observed after
five years in females and after two years in males
whereas the increased pancreatic cancer risk peaked in
the first year after diagnosis. A similar pattern was de-
tected for cervix and corpus uteri cancer in females and
kidney cancer in males.
Table 1 Patient characteristics for T2DM patients
Patients with registered date
of diabetes diagnosis (N = 5709)
Patients without registered date
of diabetes diagnosis (N = 1918)
Full analysis
(N = 7627)
Median age at onset (years) and 25 and 75 percentiles 57 48/66 64 55/73 59 50/68
Sex,% females 47.0 42.4 45.9
Distribution by year of diabetes diagnosis (quinquennium) 1988-1990: 10.7% 1988-1990: 8.0%
1991-1995: 7.3% 1991-1995: 5.5%
1996-2000: 19.2% 1996-2000: 14.3%
2001-2005: 25.5% 2001-2005: 19.1%
2006-2010: 37.3% 2006-2010: 53.1%
HbA1c(%)
1) 7.7 7.8 7.7
Obesity,% of patients with BMI≥ 30 41.4 39.1 40.8
Family history,% of patients with diabetes
in first-degree relatives
44.8 44.6 44.8
Late complications,% of patients with at
least one late complication2)
38.5 42.9 38.5
1)Data are presented as mean of measures per patient.
2)Late complications: nephropathy, retinopathy, neuropathy, foot complications, amputation, myocardial infarction, apoplexy, peripheral arterial insufficiency,
coronary artery bypass (PTCA).
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epidemiological studies published in the literature. For
pancreatic cancer Huxley et al. [2] found a risk estimate
of 1.82 (95% CI 1.71, 1.94) in a meta-analysis, and Ben
et al. [3] found a slightly higher risk estimate of 2; both
estimates fit quite well with our results of 1.78 and 1.87Table 2 Cancer risk for T2DM patients by sex and cancer site
Cancer site

















Haem&Lymph1) [C81-C85; C88; C90-C96; D45-D47]
All cancer sites except NMSC [C00-C97; D45-D47; exc. C44]
1)Neoplasms in the haematologic/lymphatic system.for women and men, respectively. Ben et al. also reported
that the risk for pancreatic cancer diagnosis peaks shortly
after diagnosis of diabetes [3]. In our study, cancer diagno-
sis was highest in the first year after entry in the DRT but
risk was increased also after a longer observation period.
A meta-analysis performed by El-Serag et al. [24] found aFemales Males
Obs SIR 95% CI Obs SIR 95% CI
2 0.40 (0.05, 1.46) 14 0.75 (0.41, 1.26)
10 1.07 (0.51, 1.97) 8 0.55 (0.24, 1.08)
27 0.94 (0.62, 1.36) 44 1.11 (0.81, 1.49)
7 2.40 (0.96, 4.94) 20 2.71 (1.65, 4.18)
16 1.78 (1.02, 2.89) 18 1.87 (1.11, 2.96)
15 0.79 (0.44, 1.30) 45 0.92 (0.67, 1.24)
9 0.82 (0.37, 1.55) 11 0.70 (0.35, 1.25)
72 1.13 (0.88, 1.42)
70 1.18 (0.92, 1.49)
10 1.81 (0.87, 3.32)
24 1.79 (1.15, 2.66)
7 0.63 (0.25, 1.29)
83 0.85 (0.68, 1.05)
4 0.89 (0.24, 2.29) 16 1.10 (0.63, 1.79)
10 1.45 (0.70, 2.67) 19 1.65 (0.99, 2.57)
0 0 (0.00, 1.18) 3 0.73 (0.15, 2.13)
8 1.65 (0.71, 3.25) 1 0.30 (0.01, 1.67)
26 1.28 (0.84, 1.87) 21 0.78 (0.48, 1.18)
234 1.05 (0.92, 1.20) 291 0.93 (0.82, 1.04)
Table 3 Cancer risk for female T2DM patients by cancer site and follow-up period
Follow-up period
Cancer site Total 1st year 2 - 5 years ≥5 years
Obs SIR 95% CI Obs SIR 95% CI Obs SIR 95% CI Obs SIR 95% CI
Head & Neck [C00-C14; C30-C32] 2 0.40 (0.05, 1.46) 0 0.00 (0.00, 8.14) 0 0.00 (0.00, 2.30) 2 0.69 (0.08, 2.51)
Stomach [C16] 10 1.07 (0.51, 1.97) 1 1.18 (0.03, 6.58) 3 1.01 (0.21, 2.94) 6 1.09 (0.40, 2.36)
Colorectum [C18-C21] 27 0.94 (0.62, 1.36) 4 1.58 (0.43, 4.05) 7 0.77 (0.31, 1.59) 16 0.93 (0.53, 1.51)
Liver [C22] 7 2.40 (0.96, 4.94) 1 4.07 (0.10, 22.70) 0 0.00 (0.00, 4.12) 6 3.37 (1.24, 7.34)
Pancreas [C25] 16 1.78 (1.02, 2.89) 7 9.51 (3.82, 19.59) 4 1.48 (0.40, 3.79) 5 0.90 (0.29, 2.11)
Lung [C33-C34] 15 0.79 (0.44, 1.30) 2 1.18 (0.14, 4.27) 4 0.66 (0.18, 1.69) 9 0.80 (0.37, 1.52)
Melanoma [C43] 9 0.82 (0.37, 1.55) 1 0.93 (0.02, 5.19) 3 0.81 (0.17, 2.35) 5 0.81 (0.26, 1.88)
Breast [C50] 72 1.13 (0.88, 1.42) 12 1.94 (1.00, 3.39) 21 0.98 (0.60, 1.49) 39 1.08 (0.77, 1.48)
Breast postmenopausal [C50] 70 1.18 (0.92, 1.49) 11 1.99 (1.00, 3.57) 20 1.02 (0.62, 1.58) 39 1.14 (0.81, 1.55)
Cervix uteri [C53] 10 1.81 (0.87, 3.32) 4 6.22 (1.69, 15.92) 2 0.96 (0.12, 3.47) 4 1.42 (0.39, 3.65)
Corpus uteri [C54] 24 1.79 (1.15, 2.66) 4 3.14 (0.86, 8.05) 5 1.13 (0.37, 2.64) 15 1.94 (1.09, 3.20)
Ovary [C56] 7 0.63 (0.25, 1.29) 1 0.95 (0.02, 5.31) 1 0.27 (0.01, 1.51) 5 0.78 (0.25, 1.81)
Bladder [C67] 4 0.89 (0.24, 2.29) 0 0.00 (0.00, 9.71) 1 0.70 (0.02, 3.92) 3 1.12 (0.23, 3.29)
Kidney [C64-C65] 10 1.45 (0.70, 2.67) 1 1.57 (0.04, 8.74) 4 1.79 (0.49, 4.59) 5 1.24 (0.40, 2.90)
Thyroid [C73] 8 1.65 (0.71, 3.25) 2 3.86 (0.47, 13.95) 3 1.69 (0.35, 4.94) 3 1.17 (0.24, 3.42)
Brain [C47; C70-C72] 0 0.00 (0.00, 1.18) 0 0.00 (0.00, 12.58) 0 0.00 (0.00, 3.55) 0 0.00 (0.00, 2.05)
Haem&Lymph1) [C81-C85; C88;
C90-C96; D45-D47]
26 1.28 (0.84, 1.87) 3 1.65 (0.34, 4.83) 5 0.78 (0.25, 1.82) 18 1.49 (0.88, 2.35)
All except NMSC [C00-C97; D45-D47;
exc. C44]
234 1.05 (0.92, 1.20) 42 1.96 (1.42, 2.66) 61 0.82 (0.63, 1.06) 131 1.03 (0.86, 1.23)
1)Neoplasms in the haematologic/lymphatic system.
Table 4 Cancer risk for male T2DM patients by cancer site and follow-up period
Follow-up period
Cancer site Total 1st year 2 - 5 years ≥5 years
Obs SIR CI Obs SIR CI Obs SIR CI Obs SIR CI
Head & Neck [C00-C14; C30-C32] 14 0.75 (0.41, 1.26) 1 0.55 (0.01, 3.07) 6 0.94 (0.35, 2.06) 7 0.67 (0.27, 1.37)
Stomach [C16] 8 0.55 (0.24, 1.08) 1 0.75 (0.02, 4.21) 4 0.85 (0.23, 2.18) 3 0.35 (0.07, 1.02)
Colorectum [C18-C21] 44 1.11 (0.81, 1.49) 6 1.72 (0.63, 3.74) 14 1.11 (0.60, 1.86) 24 1.03 (0.66, 1.53)
Liver [C22] 20 2.71 (1.65, 4.18) 1 1.55 (0.04, 8.66) 7 3.02 (1.21, 6.21) 12 2.71 (1.40, 4.74)
Pancreas [C25] 18 1.87 (1.11, 2.96) 3 3.67 (0.76, 10.73) 7 2.33 (0.94, 4.79) 8 1.38 (0.60, 2.72)
Lung [C33-C34] 45 0.92 (0.67, 1.24) 6 1.36 (0.50, 2.95) 15 0.95 (0.53, 1.57) 24 0.84 (0.54, 1.25)
Melanoma [C43] 11 0.70 (0.35, 1.25) 0 0.00 (0.00, 2.48) 6 1.14 (0.42, 2.48) 5 0.56 (0.18, 1.30)
Prostate [C61] 83 0.85 (0.68, 1.05) 12 1.35 (0.70, 2.35) 20 0.64 (0.39, 0.98) 51 0.89 (0.66, 1.17)
Bladder [C67] 16 1.10 (0.63, 1.79) 1 0.79 (0.02, 4.38) 6 1.30 (0.48, 2.82) 9 1.05 (0.48, 1.98)
Kidney [C64-C65] 19 1.65 (0.99, 2.57) 5 4.64 (1.51, 10.83) 4 1.05 (0.29, 2.70) 10 1.50 (0.72, 2.76)
Brain [C47; C70-C72] 3 0.73 (0.15, 2.13) 1 2.54 (0.06, 14.17) 0 0.00 (0.00, 2.68) 2 0.86 (0.10, 3.09)
Thyroid [C73] 1 0.30 (0.01, 1.67) 0 0.00 (0.00, 11.05) 0 0.00 (0.00, 3.21) 1 0.54 (0.01, 3.00)
Haem&Lymph1) [C81-C85; C88; C90-C96; D45-D47] 21 0.78 (0.48, 1.18) 6 2.47 (0.91, 5.37) 6 0.69 (0.25, 1.50) 9 0.56 (0.26, 1.07)
All except NMSC [C00-C97; D45-D47; exc. C44] 291 0.93 (0.82, 1.04) 41 1.37 (0.98, 1.86) 90 0.86 (0.69, 1.06) 160 0.89 (0.76, 1.04)
1)Neoplasms in the haematologic/lymphatic system.
















All cancer except NMSC
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
SIR
analysis cohort with last cancer
analysis cohort with first cancer
cohort of all DRT patients
Figure 1 Sensitivity analysis for female patients, age-adjusted SIR and 95% confidence interval for analysis cohort, analysis cohort with












All cancer except NMSC
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
SIR
analysis cohort with last cancer
analysis cohort with first cancer
cohort of all DRT patients
Figure 2 Sensitivity analysis for male patients, age-adjusted SIR and 95% confidence interval for analysis cohort, analysis cohort with
first cancer case and cohort of all patients registered in the DRT (also without date of diabetes diagnosis).
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http://www.biomedcentral.com/1471-2458/14/1058risk estimate of 2.50 (95% CI 1.93, 3.24) for liver cancer in
patients with type 2 diabetes, and some years later Wang
et al. [2] demonstrated in a meta-analysis a summary rela-
tive risk of 2.01 (95% CI 1.61, 2.51). These results are in
line with the risk observed in our study, namely 2.40 for
women and 2.71 for men. Our results are also in line with
further observations in the Wang et al. [2] paper namely
that the risk was increased in both females and males and
that the risk was stronger in studies with a follow-up
period longer than six years. In addition, Wang et al. also
showed that increased liver cancer risk for diabetes
patients. is independent of alcohol consumption and
hepatitis viral infection.
For endometrial cancer Friberg et al. [4] reported a
risk estimate of 2.10 (95% CI 1.93, 3.24) as compared to
a risk estimate of 1.79 in our study. Also, diagnosis of
endometrial cancer in our study was highest within a
short period following diagnosis of T2DM and also ele-
vated in the period beyond five years after diabetes diag-
nosis. Our study also observed an increased risk for
diagnosis of cervical cancer, which to our knowledge has
been shown only for patients with the diagnosis of type
1 diabetes mellitus [25].
For bladder cancer we found a risk estimate of 0.89 for
female and 1.10 for male patients with diabetes mellitus;
the latter is in agreement with the results of a previously
published meta-analysis showing a risk estimate of 1.24
[8]. With respect to bladder cancer the small number of
cases of this cancer entity has to be considered, which
results from very strict diagnostic definitions. Addition-
ally, several authors suggest that bladder cancer data
can hardly be compared internationally due to the lack
of uniform definitions [26].
Our analysis did not show an increased risk for colorectal
carcinoma diagnosis in patients with T2DM. We demon-
strated risk estimates of 0.94 and 1.11 for females and males,
respectively, as compared to a risk estimate of 1.40 shown in
a meta-analysis by Larsson [27]. Similar results were pub-
lished by Jiang et al. [6], Yuhara [28] and Flood [29]. We also
found no increased risk for gastric cancer (risk estimates of
1.07 for female and 0.55 for male patients with T2DM),
which is consistent with the ongoing discussion about an
increased risk for gastric cancer in Western populations
[11,13,18]. In addition, stomach cancer has decreased mark-
edly in our region and numbers are small; for Tyrol we
previously observed an age-standardized incidence risk of 5
and 11 per 100 000 females and males, respectively [22].
Our risk estimate for prostate cancer (0.85, 95% CI
0.68, 1.05) failed to reach statistical significance. How-
ever, our SIRs are in the range of those in the meta-
analysis conducted by Kasper et al. [10] showing a risk
estimate of 0.84.
In summary, our study findings agree in general with those
of published studies conducted in hospitalized patients [30].Causality of the association between diabetes mellitus
and cancer is far from being the aim of our study. Some of
the most discussed pathways between diabetes mellitus and
cancer are common risk factors, for example for endometrial
cancer (obesity), pancreatic cancer (smoking, obesity)
and breast cancer (dysregulation of female endogenous
sex hormones [31]).
Because our evaluation is based on the combined analysis
of two registries, no detailed clinical data were available for
the patients. The diabetes patients in our study were all
treated in hospitals and therefore we hypothesized that our
patients are prone to a selection towards more severe
course of diabetes. DRT entry was based on data obtained
in an out-patient department setting and thus with com-
prehensive diagnostic tools; results derived from patients
treated in private practice might be different.
For most cancer sites with increased cancer risk in T2DM
patients, risk was increased mainly in the first year after
diabetes diagnosis. For this observation made in many
studies on the association between diabetes and cancer
two main causes are under discussion, namely reverse
causality (this means that in fact cancer causes T2DM
and not that T2DM causes cancer, which was the asso-
ciation we intended to investigate) and ascertainment
bias (because the diabetes diagnosis is likely to initiate a
chain of diagnostic interventions that could result in a
cancer diagnosis occurring around the time of diabetes
diagnosis, which cancer diagnosis would not have been
made at that time without diabetes diagnosis). In general,
all studies on diabetes and cancer underlie an inherent as-
certainment bias described above. This ascertainment bias
was studied in detail, for example by Johnson et al. [32].
Reverse causality was discussed to play a role in the
association between diabetes and cancer. For pancreatic
cancer reverse causality could be the case, a theory that
is supported by the increased risk observed shortly after
diagnosis of diabetes. While it is noteworthy that we
were able to present data on SIR by time since diabetes
diagnosis, our numbers are small and therefore prone to
random variation. Risk for pancreatic cancer was higher
in the first year after diabetes diagnosis in our study too,
but a tendency towards increased risk was noticed also
after the immediate period following diabetes diagnosis.
Reverse causality seems less likely for liver cancer, be-
cause peak values for diagnosis years were observed
after T2DM diagnosis. In our study we observed ele-
vated SIR estimates during the whole follow-up period
analyzed. We also observed elevated SIR estimates after
the first year following diabetes diagnosis for kidney can-
cer (reaching borderline statistical significance for men).
Larsson et al. [7] showed in a meta-analysis of cohort
studies a tendency of stronger association in women
than in men which is not in line with our observation.
In addition, it is unclear whether the observed association
Oberaigner et al. BMC Public Health 2014, 14:1058 Page 8 of 9
http://www.biomedcentral.com/1471-2458/14/1058between diabetes and kidney cancer risk is due to de-
tection bias.
In addition to reverse causality and ascertainment bias,
both disorders can be viewed as chronological diseases with
long latency periods and diagnosis at some arbitrary time
point depending on clinical symptoms. Johnson pointed
out that the clinical conditions leading to diagnosis of
diabetes and/or cancer can be overlapping [18].
In summary, the association between T2DM and certain
types of cancer seems to be very complex. Differences and
limitations in the applied methods make it difficult to
compare study results [16,18,31]. This is also true for
the ongoing discussion about a possible influence of
glucose-lowering medication on cancer risk.
In order to investigate the possible influence of the study
design on the results of our evaluation, we also performed a
sensitivity analysis comparing our results with 1) chrono-
logical first cancer (instead of chronological last cancer)
and 2) a cohort of all cases collected in the DRT, with and
without registered date of T2DM diagnosis. While these
analyses reveal no significant differences from the overall
study results, there is a tendency towards more elevated
SIR estimates in the group of all DRT patients.
Our study has strengths and limitations. The latter are
mainly the lack of detailed clinical data, especially data
on comorbidities. In addition, it is likely that we under-
estimated the effect because the standard for computa-
tion of SIR was given by the whole population, which
includes also T2DM patients at an estimated prevalence
of at least 6%. The most severe limitation is that, like all
observational studies, also our study is prone to all po-
tential biases inherent in observational studies, lack of
confounding factors as mentioned above and also the
potential interactions of diabetes and cancer, for example
problems involving reverse causality, common risk factors,
competing risks, ascertainment bias etc. For a more de-
tailed list see [18]. The distinct strengths of this study are
the evaluation based on data from two well established
registries operating in the Austrian state of Tyrol: cancer
data were collected prospectively and the high quality of
the Cancer Registry of Tyrol has been demonstrated [19].
For all diabetes mellitus patients diagnosis was based on
clinical data, and all diabetes mellitus patients diagnosed
since 2005 were prospectively registered. The observa-
tional study was based on well-defined design principles
that were set a priori.
Conclusion
In conclusion, the main finding of this study is that the
risk for certain types of cancer is increased in patients
with T2DM in this Central European region. Neverthe-
less, it is important to interpret the results with great
caution due to inherent methodological problems. Op-
timized care programs for patients with T2DM shouldbe integrated in the recommended procedures for cancer
screening [16,33].
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